Clinical trials: Insulin Resistance Syndrome X
Adverse Effect, Atherosclerosis, Coronary
Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease
Pioglitazone, a medication of thiazolidinedione group, is capable of triggering the peroxisome proliferator-activated receptors (PPAR-γ).
- Conditions
- Adverse Effect, Atherosclerosis, Coronary, Insulin Resistance Syndrome
- Trial name
- EFFORT (NCT03011775)
- Testing
- Pioglitazone 15 mg Tablet, Isosorbide Dinitrate 10Mg Tablet, Acetylsalicylic Acid 75Mg Tablet
- Where
- Ukraine
- Volunteers
- 43 people
- Sponsor
- Ukrainian Medical Stomatological Academy
Diabetes, Metabolic Syndrome x
Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects
This study will compare how well a combination of borage and echium oils will reduce inflammation compared to fish oils and placebo oil in subjects that are diabetic or have metabolic syndrome.
- Trial name
- NCT01145066
- Testing
- borage/echium oil combination, fish oil, corn oil
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Wake Forest University Health Sciences
Metabolic Syndrome X, Prediabetic State
Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation
The relationship between obesity and insulin resistance is known, however the mechanism(s) associating obesity with insulin resistance is not well understood.
- Trial name
- NCT00470262
- Testing
- Fenofibrate 145mg PO QD, Pioglitazone 45 mg PO QD
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
HIV Infections, Metabolic Syndrome X
Lifestyle Modification and Metformin Use in the Treatment of HIV
A healthy diet and exercise have improved the health of people without human immunodeficiency virus (HIV) who have Metabolic Syndrome.
- Trial name
- NCT00399360
- Testing
- Metformin, Lifestyle Modification
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Metabolic Syndrome X
Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study
Ezetimibe has been shown to inhibit cholesterol absorption and several lines of evidence from in vitro systems and animal models suggest that this effect is associated with an increase in low-density lipoprotein (LDL) receptor…
- Trial name
- EZEmRNA (NCT01849068)
- Testing
- Ezetimibe
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Laval University
Cardiovascular Diseases, Metabolic Syndrome X
Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome
The purpose of the study is to test higher versus lower doses of aspirin on markers of atherosclerosis in patients at risk of a first heart attack.
- Conditions
- Cardiovascular Diseases, Metabolic Syndrome X, Atherosclerosis
- Trial name
- PAD (NCT00272311)
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Florida Atlantic University
Obesity, Metabolic Syndrome X
Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity
Obesity is common (>30% of US adults), contributes to substantial morbidity and mortality, but is difficult to treat. Partly this is due to the transient, arduous and modest nature of lifestyle interventions.
- Trial name
- REVIVE (NCT01351753)
- Testing
- Metformin, Orlistat, Topiramate
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- University of Iowa
Metabolic Syndrome X
Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity
The combination of high blood pressure and having central obesity is an increasing important factor for heart disease in men and women.
- Trial name
- NCT00608465
- Testing
- Eplerenone, Ramipril
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Schizophrenia, Metabolic Syndrome X
Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes
This study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage in people with…
- Conditions
- Schizophrenia, Metabolic Syndrome X, Insulin Resistance
- Trial name
- NCT00338949
- Testing
- Switch, Control
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Veterans Medical Research Foundation
Hypertension, Metabolic Syndrome X
Clinical EvaluatioN of TElmisartan-based Antihypertensive Regimen
To determine the efficacy and safety of telmisartan-based treatment among patients with metabolic syndrome in actual setting in Philippines.
- Trial name
- NCT00613314
- Where
- 122 sites in Philippines
- Volunteers
- 15,268 people
- Sponsor
- Boehringer Ingelheim
Metabolic Syndrome X
ROMEO (Rosuvastatin in Metabolic syndrOme)
The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg after 6 weeks of treatment in the ratio of ApoB/ApoA1 in subjects with metabolic syndrome.
- Trial name
- NCT00395486
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 3 sites in South Korea
- Volunteers
- 258 people
- Sponsor
- AstraZeneca
Metabolic Syndrome X
Effect of Banaba (Lagerstroemia Speciosa) on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity
The Metabolic Syndrome is a high prevalence disease worldwide. About a quarter of the adult population suffers the disease. Banaba has shown evidence that has on metabolic syndrome, insulin sensitivity and insulin secretion.
- Trial name
- NCT02767869
- Testing
- Banaba
- Where
- Mexico
- Volunteers
- 24 people
- Sponsor
- University of Guadalajara
Diabetes Mellitus, Metabolic Syndrome X
Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells
Thirty-six subjects with hyperlipidemia and metabolic syndrome and/or diabetes were randomized in a double-blind manner to either pravastatin 80 mg or atorvastatin 10 mg daily.
- Conditions
- Diabetes Mellitus, Metabolic Syndrome X, Hypercholesterolemia
- Trial name
- STOPCAP (NCT00166036)
- Testing
- Atorvastatin, Pravastatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Emory University
Insulin Resistance, Hypertriglyceridemia
Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.
Approximately 1/4 of the US population has insulin resistance and the associated risk factors such as elevated lipid levels -triglycerides (type of fat from what we eat and what the liver produces and low HDL cholesterol which is…
- Trial name
- NCT00186537
- Testing
- Rosiglitazone, Fenofibrate, Weight Loss
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Stanford University
Schizophrenia, Schizoaffective Disorder
Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome
The objective of this study is to determine the effect of various mood stabilizers (MS) on the insulin resistance syndrome (IRS; also called the metabolic syndrome) alone and in patients treated with antipsychotic drugs (APDs).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00288366
- Testing
- ziprasidone vs. aripiprazole, aripiprazole vs. ziprasidone
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Northwestern University
Metabolic Syndrome X
Efficacy Study Regarding the Beneficial Effects of Omega-3 Fatty Acids on Cardiometabolic Health
Fish oil supplements (which are rich in omega-3 fatty acids) have been shown to provide cardiometabolic benefits to individuals of all ages.
- Trial name
- FOHS (NCT02042274)
- Testing
- Fish oil supplement
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Guelph
Metabolic Syndrome X, Overweight
Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)
Metabolic syndrome consists of a group of co-occuring conditions that increase an individual's risk of developing heart disease, stroke, and diabetes.
- Conditions
- Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias
- Trial name
- ARCH-MS (NCT00455403)
- Testing
- Chloroquine
- Where
- United States
- Volunteers
- 357 people
- Sponsor
- Washington University School of Medicine
Metabolic Syndrome X, Overweight
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
Metabolic syndrome consists of a group of co-occuring conditions that increase an individual's risk of developing heart disease, stroke, and diabetes.
- Conditions
- Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias
- Trial name
- ARCH-MS (NCT00455325)
- Testing
- Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Washington University School of Medicine
Metabolic Syndrome X
Inflammation and the Metabolic Syndrome in Humans
People who are overweight are at increased risk of heart disease. Being overweight and having heart disease are linked in that both involve inflammation.
- Trial name
- LPS (NCT00954824)
- Testing
- Endotoxin (LPS)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Depressive Disorder, Major, Metabolic Syndrome X
Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome
The goal of this study is to begin to test whether or not pioglitazone, an FDA approved medication used to treat high blood sugar, may be safe and effective in treating Major Depressive Disorder (MDD) in patients with comorbid…
- Trial name
- NCT00671515
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Joseph Calabrese, MD